MX347355B - Diagnostico basado en troponina y en peptido natriuretico cerebral (bnp) de pacientes en riesgo y de causa de ataque. - Google Patents

Diagnostico basado en troponina y en peptido natriuretico cerebral (bnp) de pacientes en riesgo y de causa de ataque.

Info

Publication number
MX347355B
MX347355B MX2014003496A MX2014003496A MX347355B MX 347355 B MX347355 B MX 347355B MX 2014003496 A MX2014003496 A MX 2014003496A MX 2014003496 A MX2014003496 A MX 2014003496A MX 347355 B MX347355 B MX 347355B
Authority
MX
Mexico
Prior art keywords
stroke
troponin
cause
risk patients
based diagnosis
Prior art date
Application number
MX2014003496A
Other languages
English (en)
Other versions
MX2014003496A (es
Inventor
Hess Georg
Zdunek Dietmar
Horsch Andrea
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47049159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX347355(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014003496A publication Critical patent/MX2014003496A/es
Publication of MX347355B publication Critical patent/MX347355B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

La presente invención se refiere a un método para diferenciar de manera temprana sí un sujeto padece de ataque insquémico cardioembólico o de ataque isquémico no cardioembólico, caracterizado porque comprende determinar la cantidad de una troponina cardíaca en una muestra de un sujeto que padece de ataque isquémico, en donde la muestra ser ha obtenido no más de 6 horas después del comienzo de los síntomas del ataque isquémico.
MX2014003496A 2011-10-17 2012-10-17 Diagnostico basado en troponina y en peptido natriuretico cerebral (bnp) de pacientes en riesgo y de causa de ataque. MX347355B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11185421 2011-10-17
PCT/EP2012/070553 WO2013057135A1 (en) 2011-10-17 2012-10-17 Troponin and bnp based diagnosis of risk patients and cause of stroke

Publications (2)

Publication Number Publication Date
MX2014003496A MX2014003496A (es) 2014-07-14
MX347355B true MX347355B (es) 2017-04-24

Family

ID=47049159

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003496A MX347355B (es) 2011-10-17 2012-10-17 Diagnostico basado en troponina y en peptido natriuretico cerebral (bnp) de pacientes en riesgo y de causa de ataque.

Country Status (12)

Country Link
US (4) US20140220604A1 (es)
EP (2) EP2769227B1 (es)
JP (2) JP6117805B2 (es)
KR (2) KR101950561B1 (es)
CN (2) CN105785053B (es)
AU (1) AU2012324967B2 (es)
BR (2) BR112014007007B1 (es)
CA (1) CA2846285C (es)
ES (2) ES2595028T3 (es)
MX (1) MX347355B (es)
SG (1) SG2014014559A (es)
WO (1) WO2013057135A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108120837B (zh) 2012-11-09 2021-06-22 霍夫曼-拉罗奇有限公司 阵发性心房纤颤的基于TnT的诊断
CN107076754A (zh) * 2015-09-23 2017-08-18 博美利克斯技术公司 通过心脏病生物标志物标准浓度‑灵敏度表监控心脏病发展及治疗状态方法及生物芯片
EP3736563B1 (en) 2015-10-05 2023-11-08 University of Pittsburgh - Of the Commonwealth System of Higher Education Portable handheld tesstrip device with aptamer for decting cardac biomarkers
EP3279665B1 (en) * 2016-08-04 2020-07-08 Roche Diagniostics GmbH Circulating esm-1 (endocan) in the assessment of atrial fibrillation
KR102356418B1 (ko) * 2017-06-13 2022-02-08 에프. 호프만-라 로슈 아게 심방 세동 (af) 의 평가를 위한 지방산 결합 단백질 3
KR102170826B1 (ko) * 2018-01-18 2020-10-27 사회복지법인 삼성생명공익재단 뇌졸중 진단 또는 예후예측용 바이오마커 및 이의 용도
EP3841382A1 (en) * 2018-08-24 2021-06-30 Roche Diagnostics GmbH Circulating fgfbp-1 (fibroblast growth factor-binding protein 1) in the assessment of atrial fibrillation and for the prediction of stroke
CN114807356B (zh) * 2022-05-19 2025-02-28 苏州大学 一种nppb基因dna羟甲基化标志物、引物及其应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
WO1996037777A1 (en) * 1995-05-23 1996-11-28 Nelson Randall W Mass spectrometric immunoassay
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
DE19828466A1 (de) 1998-06-26 1999-12-30 Roche Diagnostics Gmbh Entstörung von Immunoassays durch Substanzen, die aus den Framework-Regionen von Antikörpern abgeleitet sind
US6709855B1 (en) 1998-12-18 2004-03-23 Scios, Inc. Methods for detection and use of differentially expressed genes in disease states
DE19902601A1 (de) 1999-01-23 2000-07-27 Roche Diagnostics Gmbh Verfahren und Vorrichtung zum Entnehmen analytischer Verbrauchsmittel aus einem Vorratsbehältnis
ATE348164T1 (de) 1999-05-17 2007-01-15 Bioph Biotech Entw Pharm Gmbh Neuroprotektive eigenschaften von gdf-15, ein mitglied der tgf-beta superfamilie
WO2003016910A1 (en) 2001-08-20 2003-02-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
JP3806694B2 (ja) 2001-05-04 2006-08-09 バイオサイト インコーポレイテッド 急性冠状動脈症候群の診断マーカーおよびその使用方法
WO2002098432A1 (en) * 2001-06-01 2002-12-12 The Brigham And Women's Hospital, Inc. Methods of treating cardiac disorders
US7262017B2 (en) * 2001-09-14 2007-08-28 Torrey Pines Institute For Molecular Studies Diagnostic markers for ischemia
US20030082153A1 (en) * 2001-10-22 2003-05-01 The Government Of The United States Of America Stem cells that transform to beating cardiomyocytes
CA2390820A1 (en) 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
EP1587955A4 (en) 2002-12-24 2007-03-14 Biosite Inc DIFFERENTIAL DIAGNOSTIC MARKERS AND METHODS OF USE
ATE403157T1 (de) 2004-03-15 2008-08-15 Hoffmann La Roche Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung
WO2005103720A1 (en) * 2004-03-29 2005-11-03 Medstar Research Institute, Inc. Methods of diagnosing cardiovascular disease
DE102004023402A1 (de) * 2004-05-12 2005-12-08 Roche Diagnostics Gmbh Verfahren zur Erhöhung des dynamischen Messbereichs von auf spezifischen Bindereaktionen basierenden, insbesondere immunologischen Testelementen
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
US20060003338A1 (en) 2004-06-30 2006-01-05 Deng David X System and methods for the management and treatment of vascular graft disease
US20060166303A1 (en) * 2005-01-24 2006-07-27 Eberhard Spanuth Use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs
JP4828550B2 (ja) 2005-02-17 2011-11-30 エフ．ホフマン−ラ ロシュ アーゲー 心機能障害を診断するためのＮＴ−ｐｒｏＡＮＰ／ＮＴ−ｐｒｏＢＮＰ比の使用
EP1731910A1 (en) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
ES2273599B1 (es) * 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
EP1816477A1 (en) * 2006-02-06 2007-08-08 F. Hoffmann-la Roche AG The use of natriuretic peptides and placenta growth factor levels for risk stratification of individuals elected for cardiac stress testing
US7838250B1 (en) * 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
BRPI0712607A8 (pt) * 2006-05-25 2019-06-04 Biogen Idec Inc métodos de tratamento de acidente vascular cerebral
EP1862805A1 (en) * 2006-06-01 2007-12-05 University of Zürich The use of mrp 8/14 levels for discrimination of individuals at risk of acute coronary syndromes
WO2008015254A2 (en) 2006-08-04 2008-02-07 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on gdf-15
BRPI0716416A2 (pt) * 2006-08-08 2016-10-11 Mayo Foundation polipeptídeo substancialmente puro entre 37 e 47 besíduos de aminoácido de comprimento, ácido nucléico isolado, vetor: célula hospedeira e composição farmacêutica
US20080050749A1 (en) * 2006-08-17 2008-02-28 Ildiko Amann-Zalan Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents
IS8576A (is) * 2006-12-05 2007-01-15 Decode Genetics Genetic susceptibility variants of atrial fibrillation and stroke
CA2673123C (en) 2006-12-05 2019-04-30 Decode Genetics Ehf. Genetic markers for risk management of cardiac arrhythmia
EP2498095A3 (en) 2007-01-25 2012-11-28 Roche Diagniostics GmbH Use of IGFBP-7 in the assessment of heart failure
EP2311981B1 (en) * 2007-05-01 2014-09-17 The Regents of The University of California Methods for diagnosing ischemia
EP2037278A1 (en) * 2007-09-11 2009-03-18 F.Hoffmann-La Roche Ag Vascular markers in the remodelling of cardiac injury
PL2040072T3 (pl) * 2007-09-22 2013-06-28 Hoffmann La Roche System analityczny do określania koncentracji analitu w płynie ustrojowym
JP2011501112A (ja) 2007-10-10 2011-01-06 エフ．ホフマン−ラ ロシュ アーゲー 心筋梗塞のモニタリング及びその治療のための手段及び方法
JP2011501113A (ja) * 2007-10-10 2011-01-06 エフ．ホフマン−ラ ロシュ アーゲー 急性冠症候群を有する患者での既存の心筋機能不全の評価のためのナトリウム利尿ペプチド／トロポニン比
US20090233312A1 (en) * 2007-10-10 2009-09-17 Nanosphere, Inc. Methods and assays to assess cardiac risk and ischemia
US8835183B2 (en) * 2008-01-07 2014-09-16 Ortho-Clinical Diagnostics, Inc. Determination of sFlt-1:angiogenic factor complex
JP2011528115A (ja) 2008-07-14 2011-11-10 エフ．ホフマン−ラ ロシュ アーゲー 心不全を有する患者の診断、モニター及び治療の選択のためのマルチマーカーパネル
WO2010017972A1 (en) * 2008-08-13 2010-02-18 Roche Diagnostics Gmbh D-dimer, troponin, nt-probnp for pulmonary embolism
WO2010046136A1 (en) * 2008-10-24 2010-04-29 B.R.A.H.M.S. Ag Prognosis and risk assessment in stroke patients by determining the level of marker peptides
EP2425245B1 (en) 2009-04-27 2016-10-05 Roche Diagnostics GmbH Use of endostatin as a marker of heart failure
WO2011012268A1 (en) 2009-07-27 2011-02-03 Roche Diagnostics Gmbh Use of mimecan in the assessment of heart failure
EP2609427B1 (en) 2010-08-26 2015-01-21 Roche Diagnostics GmbH Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure
ES2680149T3 (es) 2012-09-12 2018-09-04 F. Hoffmann-La Roche Ag Identificación de pacientes con fracción de acortamiento anormal
EP2730923A1 (en) 2012-11-09 2014-05-14 Roche Diagniostics GmbH NTproBNP and cTnT based therapy guidance in heart failure
CN113759128A (zh) 2012-12-04 2021-12-07 霍夫曼-拉罗奇有限公司 心力衰竭疗法的选择中的生物标记物

Also Published As

Publication number Publication date
AU2012324967B2 (en) 2015-09-17
CA2846285C (en) 2019-09-24
JP6117805B2 (ja) 2017-04-19
CN105785053A (zh) 2016-07-20
CA2846285A1 (en) 2013-04-25
CN103998938A (zh) 2014-08-20
SG2014014559A (en) 2014-08-28
JP2014535047A (ja) 2014-12-25
ES2824110T3 (es) 2021-05-11
BR112014007007A2 (pt) 2017-04-11
WO2013057135A1 (en) 2013-04-25
KR20140059864A (ko) 2014-05-16
CN103998938B (zh) 2016-06-15
US11047865B2 (en) 2021-06-29
ES2595028T3 (es) 2016-12-27
EP2769227A1 (en) 2014-08-27
MX2014003496A (es) 2014-07-14
JP6412085B2 (ja) 2018-10-24
BR112014007007B1 (pt) 2022-04-19
KR20160090913A (ko) 2016-08-01
HK1196158A1 (zh) 2014-12-05
BR122021026652B1 (pt) 2022-08-23
US20160011210A1 (en) 2016-01-14
US20140220604A1 (en) 2014-08-07
EP3088900A1 (en) 2016-11-02
AU2012324967A1 (en) 2014-03-13
US20180196066A1 (en) 2018-07-12
EP2769227B1 (en) 2016-07-27
AU2012324967A8 (en) 2014-03-20
EP3088900B1 (en) 2020-08-12
US20170023588A1 (en) 2017-01-26
KR101643147B1 (ko) 2016-07-27
CN105785053B (zh) 2018-09-21
JP2017049267A (ja) 2017-03-09
KR101950561B1 (ko) 2019-02-20

Similar Documents

Publication Publication Date Title
AU2012324967A8 (en) Troponin and BNP based diagnosis of risk patients and cause of stroke
EA201391187A1 (ru) Способ диагностики злокачественной опухоли и набор для диагностики путем измерения активности nk-клеток
PL2986735T3 (pl) Sposób określania składu ilościowego komórek krwi w próbce
MX2018008882A (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
IN2014CN04326A (es)
WO2011092285A3 (en) Means and methods for diagnosing heart failure in a subject
MY194587A (en) Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
HK1199099A1 (en) Methods and compositions for the treatment and diagnosis of cancer
IN2015DN00678A (es)
MX360479B (es) Anticuerpos contra microbioma, factores de estres y marcadores de mastocitos como marcadores de diagnostico para ibs.
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
WO2012094550A3 (en) Assays and methods of treatment relating to vitamin d insufficiency
MX2015008436A (es) Composiciones para permeabilizar celulas sanguineos fijos y sus usos.
EA201300817A1 (ru) Способ улучшенного приживления гемопоэтических стволовых клеток
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
MX389029B (es) Metodos para valorar la pureza de una preparacion de celulas germinales mesenquimales
NZ711543A (en) Anti-cd83 antibodies and use thereof
FI20115670A0 (fi) Kardiovaskulaarinen in vitro-malli
WO2014179737A3 (en) Assays and methods of treatment relating to vitamin d insufficiency
EP2571504A4 (en) Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal
WO2014047442A3 (en) Biomarkers for assessing treatment of sialic acid deficiency diseases and conditions
WO2011083461A3 (en) Method for diagnosing and monitoring schizophrenia and tauopathies
MX2015009726A (es) Metodo para la prediccion de la aparicion de sintomas extrapiramidales (sep) inducidos por un tratamiento con antipsicoticos.
WO2011163639A3 (en) Cell aging as a unique biomarker of major depression

Legal Events

Date Code Title Description
FG Grant or registration